Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.